SNO 2021: VT1021 Demonstrates Promising Single-Agent Clinical Activity Against Recurrent GBM
Subjects with high CD36 and CD47 expression were most likely to benefit.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.